A Study of Genetically Targeted Enzyme Replacement Therapy for Advanced Heart Failure
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 250 participants.
Also called NCT01643330
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 250 participants
- Sponsor
- Celladon Corporation
- Registry
-
NCT01643330 -
2012-001700-37
-
- Main results
- Calcium upregulation by percutaneous administration of gene therapy in patients with cardiac disease (CUPID 2): a randomised, multinational, double-blind, placebo-controlled, phase 2b trial
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- United States, Belgium, Denmark, Germany, Hungary, Israel, Netherlands, Poland, Sweden, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT01643330. Randomized; quadruple masking; primary purpose treatment. Start 2012-07 (registry gives no type); primary completion 2015-02 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study of Genetically Targeted Enzyme Replacement Therapy for Advanced Heart Failure
- Acronym
- CUPID-2b
- Condition
- Ischemic Cardiomyopathy
- Condition
- Non-ischemic Cardiomyopathy
- Condition
- Heart Failure
- Condition
- Cardiomyopathies
- Intervention (Genetic)
- AAV1/SERCA2a (MYDICAR)
- Intervention (Genetic)
- Placebo
- Lead sponsor
- Celladon Corporation
Record details
- Record id
cardio:ct-nct01643330- Content hash
e0aa41624e727bfa1cfc123030926bdc70aaee9e924a92799845f4822da3a6be